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Abstract
Tourette syndrome (TS) is a neuropsychiatric disorder with childhood onset. The core 
symptoms are motor and vocal tics. The majority of patients also suffer from psychiatric 
comorbidities. The pathophysiology of TS is not clear, but changes in different neu-
rotransmitter systems—in particular the dopaminergic system—have been confirmed. 
Since there is increasing evidence that cannabis-based medicine (CBM) is effective in the 
treatment of TS, an involvement of the endocannabinoid system in the pathophysiology 
of TS has been suggested. The purpose of this chapter is to present existing evidence sug-
gesting a pathophysiological role of the endocannabinoid system in TS and to summarize 
available data on beneficial treatment effects of CBM in patients with TS.
Keywords: Tourette syndrome, cannabis-based medicine, tics, THC, cannabinoids, 
cannabis
1. Introduction
1.1. Symptoms of Tourette syndrome
Tourette syndrome (TS) is a childhood onset neuropsychiatric disorder that is present in 
approximately 1% of the population [1]. For unknown reasons, it occurs 3–4 times more often 
in men than in women. To fulfill the diagnostic criteria for TS, multiple motor and at least one 
vocal tic must be present for a minimal period of 1 year before 18 years of age.
Tics are sudden, repetitive involuntary movements or vocalizations. Both vocal and motor 
tics can be further differentiated into a simple or complex presentation. Simple motor tics 
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involve only one group of muscles in a brief jerk-like movement, with examples such as eye 
blinking, head jerking or shoulder shrugging. Complex motor tics, on the contrary, involve 
multiple groups of muscles or resemble purposeful movements. Examples of complex motor 
tics are as follows: touching people or objects, echopraxia (mirroring another person’s actions) 
or copropraxia (involuntary performing of obscene gestures). Simple vocal tics are short 
vocalizations, for example throat clearing, sniffing or grunting. Complex vocal tics involve 
the involuntary production of words or entire sentences, for example echolalia (repeating 
another person’s words), palilalia (repeating one’s own words) and coprolalia (involuntary 
pronunciation of obscene words). Although coprolalia is often associated with TS, it is only 
present in approximately 10% of patients [2]. The majority of patients report a premonitory 
urge that proceeds the tics. This is often described as an “uncomfortable” physical sensation 
located in a particular body part or as a more generalized feeling [3]. Most (adult) patients are 
able to control their tics for a short period of time.
In almost 90% of TS patients, tics are accompanied by other co-occurring psychiatric disor-
ders such as attention deficit/hyperactivity disorder (ADHD), obsessive–compulsive disorder 
(OCD), self-injurious behaviors (SIB), anxiety disorders and depression [4].
1.2. Course and causes of Tourette syndrome
Tics typically first emerge between 5 and 7 years of age and increase in severity until they 
reach a peak in early adolescence (most often at the age of 10–12 years). After this worst-ever 
period, tics—in most cases—decrease until a mild to minimal degree of severity is reached 
in early adulthood [5]. At the same time, TS is characterized by spontaneous fluctuations and 
waxing and waning over time. The occurrence of tics is influenced by various environmental 
factors. While the majority of patients experience fewer tics when relaxing or concentrating 
(e.g. when practicing sports, playing musical instruments or computer games), tics often 
increase with stress, tiredness and infections.
To date, no single cause of TS was identified; instead, several lines of evidence suggested that 
TS is caused by an interplay between genetic [6] and environmental factors [7]. For example, 
there is clear evidence that prenatal and perinatal complications including low birth weight 
and maternal smoking during pregnancy [8, 9] may represent such epigenetic factors. In 
contrast, the influence of infections [7] and immunological factors [10] is still unclear. As for 
the pathophysiology of TS, most studies suggest a major involvement of the dopaminergic 
system [11–17]; however, several other neurotransmitter systems might play a role including 
the serotonergic [12, 18], histaminergic [19], glutamatergic [20], GABAergic [21], cholinergic 
[22], and noradrenergic systems [23]. Furthermore, it is believed that disturbances of cortico-
striato-thalamo-cortical (CSTC) pathways play a role in the generation of tics [24].
1.3. Treatment of Tourette syndrome
Both European [25–27] as well as Canadian [28] treatment guidelines for TS recommend appli-
cation of behavioral psychotherapy techniques (either habit reversal training or exposure and 
response prevention training), pharmacotherapy and, in otherwise treatment resistant very 
severely affected patients, surgical intervention using deep brain stimulation. Like in the case 
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of many psychiatric disorders, treatment is only available on a symptomatic level. Available 
treatments for TS alleviate symptoms to more tolerable degree quite successfully, but cannot 
eradicate tics completely. However, treatment for tics is not necessary in all cases, but should 
be taken into consideration, when tics interfere with daily life functions or cause significant 
emotional distress. The drugs most often used in the treatment of tics are atypical antipsy-
chotics including aripiprazole, risperidone, sulpiride, and (in Germany) tiapride. If these 
drugs are not effective or not well tolerated, only few alternative options remain, including 
alpha-2-agonists (in case of comorbid ADHD), topiramate, tetrabenazine and, rarely, botuli-
num toxin. While the antipsychotics are by far the most widely used drugs for the treatment 
of TS, they bring along considerable side effects load such as sedation, weight gain, metabolic 
changes, and acute dyskinesia [25].
In summary, a large number of patients with TS are unsatisfied with available treatments—
either due to insufficient efficacy or because of clinically relevant side effects—and therefore, 
further treatment alternatives need to be developed.
2. Possible role of the endocannabinoid system in Tourette 
syndrome
The main function of the central endocannabinoid system (ECS) is inhibitory modulation of 
other neurotransmitter systems. Among other brain regions, cannabinoid type 1 receptors 
(CB1) are expressed with high density in the basal ganglia [29] indicating a paramount role of 
the ECS in the control of movements. In TS, there is substantial evidence for an involvement of 
the dopaminergic system. However, until today it is unclear, whether these alterations repre-
sent the primary cause of the disease or are related to secondary or compensatory changes. In 
addition to the dopaminergic hypothesis in TS, changes in several other transmitter systems 
have been suggested including the glutamatergic, GABAergic, serotonergic, noradrenergic 
and histaminergic systems. Since the ECS is a highly important modulatory system in the brain 
that influences and controls all important neurotransmitter systems, it can be speculated that 
TS might be caused by a dysfunction in the ECS system. This hypothesis is in line with studies 
reporting about an involvement of several different neurotransmitter systems in TS. In addi-
tion, alterations within the ECS would explain the complex clinical presentation of TS includ-
ing both hyperkinetic movements with tics and a large variety of psychiatric manifestations.
Noteworthy, there is a strong interaction between the dopaminergic and the ECS [29, 30], 
particularly in basal ganglia regions including the striatum [31] and the globus pallidus [32]. 
Since there is substantial evidence for an involvement of the dopaminergic system in the 
pathobiology of TS, it, therefore, can also be speculated that CBM may inhibit dopaminergic 
activity in brain areas associated with motor control resulting in a reduction of hyperkinetic 
movements such as tics [33]. However, one might also speculate that the modulation of 
other neurotransmitter systems including glutamate and GABA might result in a reduction 
of tics.
Until today, only one neuroimaging study has been performed using single photon emission 
computed tomography (SPECT) and [123I]AM281 to investigate the ECS in patients with TS [34]. 
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In this study, it could be demonstrated that CB1 receptor binding is reduced after treatment 
with THC. Since in this study, no control group has been included, no statement is possible, 
whether CB1 receptor binding is changed in patients with TS. So far, genetic analyses failed to 
demonstrate any genetic variations in the cannabinoid receptor gene (CNR1) in TS [35].
3. Cannabis-based medicine in patients with Tourette syndrome
3.1. Retrospective reports on self-medication
A substantial number of patients with TS report using cannabis illegally in order to improve 
their tics or comorbid psychiatric disorders. While doing so, most of these patients rely on 
their own judgment and self-medicate without a proper consultation with their treating phy-
sician. Such an observation was first described in two small case series published in 1988 and 
1993 [36]. Sandyk et al. [37] described three male patients, who benefitted both in terms of 
tics and comorbid psychiatric symptoms after smoking 0.5–2 marijuana cigarettes per day. 
Hemming et al. [36] reported a case of a 36-year-old man, who smoked a marijuana cigarette 
every day and claimed to be symptom-free for 1 year. More recently, Müller-Vahl et al. [38] 
conducted a retrospective survey about self-medication with cannabis in 64 patients with TS 
seen at a specialized Tourette outpatient clinic in Germany. Seventeen patients indicated to 
use marijuana illegally as self-treatment for their symptoms, and 14 of them reported ben-
eficial effects not only on tics, but also on different comorbidities. Interestingly, none of the 
patients reported clinically relevant adverse events (AEs) or a deterioration of tics after the 
use of marijuana. This effect was not influenced by concomitant use of antipsychotics or selec-
tive serotonin reuptake inhibitors (SSRIs).
Finally, Abi-Jaoude et al. [39] in Canada reported results from a retrospective analysis inves-
tigating efficacy and safety of smoked cannabis in 19 adults with TS. Patients experienced an 
average improvement of their tic severity measured with the Total Tic Score (TTS) of the Yale 
Global Tic Severity Scale (YGTSS) of approximately 60%. Altogether, 18 out of 19 patients 
experienced an improvement of their TS symptoms. All patients included in this study had 
used cannabis for self-medication for more than 1 year. Most often reported AEs were a feel-
ing of “being high”, decreased concentration, increased anxiety, increased appetite, seda-
tion, irritability, dry mouth, and dry eyes. However, no serious adverse events (SAEs) were 
reported.
3.2. Prospective case studies using different cannabis-based medicines
To date, there is a small number of prospective case studies available providing increasing 
evidence that CBM might be effective and well tolerated in adults with TS. Interestingly, in 
these case reports, different CBMs have been used. While most of these studies report about 
beneficial effects in adults, only very recently, first promising case reports in minors have 
been published.
Recent Advances in Cannabinoid Research122
3.2.1. Case studies using tetrahydrocannabinol
In 1999, Müller-Vahl et al. [40] published the first case of a 25-year old patient with TS treated 
with oral tetrahydrocannabinol (THC). This patient suffered from a complex TS and a number 
of additional psychiatric disorders such as ADHD, obsessive–compulsive behavior (OCB), 
SIB, anxiety disorder, and impulsivity. According to the patient’s report, self- medication 
with smoked cannabis (2–3 g/day) caused a clinically relevant improvement of all these 
symptoms. Therefore, the patient was prospectively treated once with a single dose of 10 mg 
THC. This resulted in a significant reduction of tics of about 80% as well as an improvement 
in attention, impulse control, OCB, and premonitory urges. In addition, neuropsychological 
tests showed improvements in signal detection, sustained attention, and reaction time in the 
absence of AEs.
The same group described another case of a 24-year old female, who had an improvement of 
tics and premonitory urges after combined therapy of THC and the antipsychotic amisulpride 
[41]. The patient did far better on this combination than on monotherapy with either THC or 
amisulpride.
In addition, in 2011, Brunnauer et al. [42] reported the case of a 42-year-old male with TS, 
who suffered from multiple motor and vocal tics as well as OCB. Treatment with 15 mg THC 
resulted in a 75% tic reduction. As this patient was a professional driver, his driving abilities 
were assessed by professional computerized tests. Interestingly, the patient’s concentration 
and visual abilities improved after THC administration.
Finally, Jakubovski and Müller-Vahl [43] reported about a 16-year old patient with vocal tics 
resembling stuttering-like phenomena accompanied by multiple simple and complex vocal 
tics as well as simple motor tics. Apart from tics, he was also experiencing further psychiat-
ric problems including rage attacks, sleeping problems, tic-related anxiety and shame about 
speaking in public, depressed mood, and OCB (e.g., ordering of pencils, not just right feeling, 
and rumination) resulting in difficulties concentrating. Due to treatment resistance and intol-
erable AEs after established therapeutic interventions, it was decided to implement treatment 
with vaporized THC (up to a maximum dose of 22.4–33.6 mg THC/day). This leads to an 
improvement of his tics including complex vocal tics resulting in improved speech fluency. 
Moreover, coexisting psychiatric conditions improved.
3.2.2. Case studies using nabiximols
The first case report about effective treatment with nabiximols in a patient with TS was pub-
lished by Trainor et al. [44] in 2016. This 26-year-old male suffered from treatment-resistant 
TS with severe motor and vocal tics, OCD, SIB, and depression. Administration of 4 puffs 
nabiximols (=10.8 mg of THC and 10 mg cannabidiol (CBD)) resulted in a 85% reduction of 
motor and 90% reduction of vocal tics after 4 weeks of treatment measured via the Rush Video 
Tape Rating Scale [45] and a 35% tic improvement according to the YGTSS-TTS. No AEs were 
reported.
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Another single case study using nabiximols was reported by Kanaan et al. [46]. This was a 
22-year-old male with complex and severe treatment resistant TS. Nabiximols (up-titrated to 
9 puffs/day = 24.3 mg THC and 22.5 mg CBD) resulted in a reduction of tics measured with 
YGTSS-TTS, Tourette’s Syndrome Symptom List (TSSL), and Rush Video Tape Rating Scale, 
premonitory urges, and a general improvement of quality of life without causing clinically 
relevant AEs.
3.2.3. Case studies using medicinal cannabis
Recently, Jakubovski and Müller-Vahl published a case report of a patient with TS treated 
with medicinal cannabis [43]. He suffered from a rare form of TS: a severe, impairing and 
treatment resistant vocal blocking and stuttering-like vocal tics as well as palilalia. These 
symptoms significantly impaired social contacts and daily living. The 19-year old patient 
received medicinal cannabis at a dose of 0.1 g cannabis once daily. After 8 months of follow-
up, the symptoms improved significantly, especially speech fluency, but also other tics. After 
cannabis inhalation, beneficial effects lasted for about one and a half hour. Although the acute 
effect resolved thereafter, he experienced an overall positive effect during most time of the 
day. Only at the beginning of the treatment, he experienced a “high sensation” that resolved 
later on.
3.2.4. Treatment of minors with Tourette syndrome using cannabis-based medicines
Until today, only three single case studies are available reporting about treatment of minors 
with TS using CBM. The first report was published by Hasan et al. [47] in 2010. They described 
a 15-year old adolescent with severe and treatment resistant TS and comorbid ADHD. In this 
boy, augmentation of preexisting medication with risperidone (1 mg), aripiprazole (10 mg), 
and methylphenidate (15 mg) with oral THC (gradually up-titrated to 15 mg/day during 
9 weeks) resulted in a significant tic reduction (global score of the YGTSS (range, 0–100) 
decreased from 97 to 54) and improved quality of life. The only AE observed was mild and 
transient euphoria.
The first ever case report of a child with TS treated with CBM was published only recently 
by Szejko et al. [48]. This 7-year-old boy suffered from severe tics and comorbid ADHD, 
which prevented him to attend school and finally resulted in social isolation, depression, and 
suicidal ideation. As all previous therapies including behavioral interventions and various 
medications (including risperidone, aripiprazole, tiapride, methylphenidate, and guanfacine) 
turned out to be unsuccessful, THC was proposed as a therapy of last choice. THC (in com-
bination with risperidone (2 mg/day) and guanfacine (2 mg/day)) were gradually up-titrated 
to a maximal dose of 29.4 mg/day. Follow-up for more than 4 months demonstrated not only 
a clinically relevant improvement of tics, but also of accompanying psychiatric symptoms 
resulting in overall improved quality of life and social performance. Despite the relatively 
high dose of THC, no AEs were reported.
Furthermore, there is another single case report available describing beneficial effects of a 
combined treatment with vaporized medicinal cannabis and oral THC in a 12-year-old boy 
with TS (unpublished data, under revision). The boy complained of severe motor tics causing 
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significant insomnia. Therefore, the boy’s parents—both of whom were medical doctors—
decided to medicate their son with 0.02 g vaporized cannabis (Bedrocan® variety containing 
22% THC and 1% CBD, corresponding to a dose equivalent of 4.4 mg THC). This resulted—
according to their reports—in a tremendous symptom improvement. Because of a further 
tic increase, the family presented at our Tourette outpatient clinic. Since the family reported 
about an ongoing effect while using cannabis with a relevant tic decrease, we decided to 
implement a combined treatment with vaporized medicinal cannabis (up to 0.1 g cannabis 
per day, varieties Bedrocan® and Amnesia Haze®, corresponding to 22 mg THC/day) plus 
oral THC drops (up to 12.5 mg/day). This combined therapy resulted not only in a marked tic 
reduction, but also an improvement of premonitory urges without any AEs.
Thus, currently, the database for treatment of minors with TS using CBM is very limited. 
However, from available preliminary results, it is suggested that CBM is effective and well 
tolerated even in this age group. At present time, no long-term follow-up data are avail-
able, and therefore, no statement is possible about positive and possible negative long-term 
effects, in particular with respect to detrimental effects on the developing brain. From 
observational oncological studies in children, however, it is also suggested that controlled 
application of CBM is safe and well tolerated. It is unknown, whether in children with TS 
the risk for psychosis is increased after treatment with CBM comparable to the increased 
risk in healthy children after excessive recreational cannabis use. Assuming a dysfunction in 
the ECS in TS, it can also be speculated that CBM may have beneficial effects on the course 
of the disease.
3.2.5. Controlled trials using tetrahydrocannabinol
Up to this date, only two small controlled studies have been conducted in adult patients with 
TS using CBM. Both of them were performed by Müller-Vahl’s group. Dr. Müller-Vahl is an 
internationally renowned expert in the field of TS and tic disorders. She introduced CBM in 
the treatment of TS, conducted the first randomized controlled trials in this group of patients 
in the early 2000s, and since then dedicated a large part of her research endeavors in this area. 
In both controlled studies, efficacy and safety of pure THC have been investigated. The first 
one, published in 2002 by Müller-Vahl et al. [48], was a randomized double-blind placebo-
controlled cross-over single-dose trial using 5.0, 7.5 or 10 mg of THC. The trial included 12 
adult TS patients with a mean age of 34 ± 13 years. Tic severity was assessed both via a self-rat-
ing (TSSL) and different examiner-rating scales (Shapiro Tourette’s syndrome Severity Scale 
(STSSS) and YGTSS). The Tourette’s syndrome Global Impression Scale (TS-CGI) was used to 
assess global disease severity. To assess changes in psychiatric comorbidities (including OCB, 
ADHD, and anxiety), the self-assessment of the TSSL was used. According to TSSL, there 
was a significant improvement of tics and OCB compared to placebo. According to examiner 
rating scales for the assessment of tic severity, there was an improvement in the subscore 
“complex motor tics” and a trend toward a reduction in the subscores “motor tics,” “simple 
motor tics” and “vocal tics.” The following AEs were recorded: headache, nausea, dizziness, 
tiredness, cheerfulness, dry mouth, anxiety, sensitivity to noise and light, ataxia and poor 
concentration, but no SAEs were reported. Plasma levels of the THC metabolite 11-hydroxy-
delta-tetrahydrocannabinol correlated with tic reduction as assessed by TSSL.
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In 2003, Müller-Vahl et al. published results of a randomized, double-blind, placebo-con-
trolled follow-up trial [49]. In this study, 24 adult patients with TS were treated for a period 
of 6 weeks with up to 10 mg THC/day. Tic severity was evaluated at six different time points. 
For tic assessment, both self-rating scales as well as examiner rating scales were used (TSSL, 
YGTSS, STSSS, and Rush Video-Based Tic Rating Scale) [45]. Nearly all rating scales indicated 
a significant superiority of the THC arm compared to placebo at visits 3 and 4. The Rush 
Video-Based Tic Rating Scale also showed a significant difference or trends toward significant 
group differences at visits 2 and 4 for the items “motor tic intensity” and “motor tic frequency,” 
respectively. Seven patients dropped out of the study, but only one due to AEs (restlessness 
and anxiety). Five patients in the THC group reported AEs (tiredness, dry mouth, dizziness 
and fuzziness), while three in the placebo group (tiredness, dizziness, anxiety, depression) in 
the absence of SAEs.
3.2.6. Efficacy of cannabis-based medicines in the treatment of psychiatric comorbidities in 
patients with Tourette syndrome
Up to 90% of patients with TS suffer from psychiatric comorbidities and studies investigating 
quality of life in these patients clearly demonstrate that most patients are more impaired by 
ADHD, OCD, and depression, respectively, than their tics. Thus, in the majority of patients 
with TS, effective treatment of comorbidities is even more important than treatment of tics. 
Until today, however, there is no treatment strategy known that improves both tics and 
comorbidities. Therefore, in patients with complex TS combined therapy using different treat-
ment strategies in parallel is inevitable.
Interestingly, from all available case studies and controlled trials, it is suggested that CBM 
improves not only tics, but also psychiatric symptoms. Therefore, it can be speculated that 
CBM might be the first treatment strategy that is useful in the treatment of the complete spec-
trum of symptoms. More specifically, there is preliminary evidence that CBM also improves 
ADHD [39], OCB/OCD [40] impulsivity [43], depression [50], sleeping problems [51], and 
anxiety [43].
For example, in the retrospective survey by Abi-Jaoude et al. [39], all patients reported in 
addition to the tic improvement also an improvement of psychiatric symptoms after treat-
ment with cannabis including sleeping disturbances, anxiety, OCB, impulsivity, irritability 
and rage attacks. With respect to comorbid ADHD, only one out of 13 patients demonstrated 
no improvement of ADHD symptoms. This data in patients with TS is in line with preliminary 
results in patients suffering from pure ADHD (without tics or TS). In 2017, Cooper et al. [52] 
published results of a randomized placebo-controlled pilot study using nabiximols in patients 
with ADHD. In this trial, 30 adults with ADHD were included, and cognitive performance 
was assessed using an objective assessment for inattention, hyperactivity, and impulsivity 
(Qb-Test). Although for the primary outcome, no significant difference was observed, sev-
eral secondary outcomes demonstrated superiority of nabiximols compared to placebo with 
improvements in hyperactivity, impulsivity and inattention, respectively. In the active group, 
three mild AEs and one SAE (muscular spasms/seizures) were recorded, while in the placebo 
group, one SAE (cardiovascular problems) occurred.
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Although most patients with TS treated with CBM report about an improvement of one or 
even more psychiatric comorbidities, larger controlled trials are needed to confirm these 
promising, but preliminary results.
3.2.7. Safety profile and influence on psychomotor functioning in patients with Tourette 
syndrome
From the available preliminary results, it is suggested that—on average—the AE profile of 
CBM in the treatment of patients with TS is very similar to that in other groups of patients. In 
line with data from recent meta-analyses including mixed patients’ groups [52], for example, 
in the retrospective study by Abi-Jaoude et al. [53], a relatively high number of AEs were 
reported in patients with TS, but most AEs were mild and transient, respectively. Most often 
reported AEs after use of cannabis in patients with TS were a “feeling of high,” decreased 
concentration, decreased short-term memory, increased anxiety, increased appetite, sedation, 
irritability, dry mouth and eyes, and wheezing.
Contrary to these reports from open uncontrolled studies, from preliminary controlled data, 
it is suggested that the impact of THC on neuropsychological performance in adults with TS 
may differ as compared to both healthy people and other patient groups. In two controlled 
studies investigating the effects of THC in patients with TS, additionally, neuropsychological 
tests were performed. In the first study [54], the influence of a single dose treatment of THC 
on neuropsychological performance was investigated. However, no negative impact of THC 
compared to placebo was found on verbal and visual memory, reaction time, intelligence, 
sustained attention, divided attention, and vigilance. In another study, Müller-Vahl et al. [55] 
investigated the influence of a 6-week THC treatment as compared to placebo on neuropsy-
chological performance using different neuropsychological tests to assess verbal learning, 
attention, and memory. Again, THC had no detrimental effects on neuropsychological per-
formance and immediate verbal memory span even improved after treatment with THC.
These results are completely in line with observations in two open uncontrolled single case studies. 
In 2007, Strohbeck-Kühner et al. [56] published a case of a 28 year-old male with ADHD (without 
TS), who benefitted from treatment with THC, and, moreover, his fitness to drive improved after 
treatment. A similar case was reported by Brunnauer et al. [42] some years later. They described 
an effective treatment with THC in a 42 year-old male. Furthermore, his driving ability (concentra-
tion and visual abilities) was better under treatment with THC as compared to the off-medication 
state. The authors, therefore, suggested that in TS, CBM such as THC may have beneficial effects 
on psychomotor functions related to driving performance. Thus, from this preliminary data, it 
is strongly suggested that the influence of CBM on neuropsychological performance in patients 
with TS may differ from effects in healthy people and other groups of patients.
Finally, until today, very little is known about safety of CBM in children and adolescents with TS 
[47–49]. However, from available preliminary case reports, it is suggested that in this group of 
patients CBM such as THC is well tolerated or even better tolerated than in adults. This observa-
tion is in line with reports in other groups of young patients. For example when using CBM in 
antineoplastic therapy [30] it has been suggested that CBM—even at high doses—are well toler-
ated in children.
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3.2.8. Practical clues for the treatment of patients with Tourette syndrome using cannabis-
based medicines
Despite lack of clear evidence, recent European [25] and Canadian treatment guidelines [28] 
for TS acknowledged available data and recommend CBM in otherwise treatment resistant 
adult patients with TS. Most experts suggest treatment with CBM, before taking surgical 
treatment with deep brain stimulation into consideration. Comparable to most other indica-
tions, until today it is unclear, which CBM is the most effective and best tolerated in patients 
with TS. However, from available data, it is suggested that pure CBD is not effective in the 
treatment of tics. Data obtained from both a retrospective and prospective survey performed 
at the Tourette outpatient clinic at Hannover Medical School, Germany, provide preliminary 
evidence that medicinal cannabis might be superior to pure THC and nabiximols (unpub-
lished data). Currently, treatment with CBM in minors with TS should be only taken into 
consideration in otherwise treatment resistant and severely affected patients.
With respect to the dose, no clear recommendation can be given. In any case, starting dose 
should be low (corresponding to 2.5 mg THC/day) and up-titration should be slow, for exam-
ple by 2.5 mg THC every 3–5 days. Maximal dose differs from patient to patient, but usually 
ranges from 0.1 to 1 g cannabis/day, corresponding to about 2.5–30 mg THC/day. However, 
in individual patients, maximal doses can be much higher.
An overview on all available studies investigating efficacy and safety of CBM in TS is given 
in Table 1.
Reference Number 
of patients 
(sex)
Age Substance Study design Outcome
Sandyk et al. 1988 3 (male) 15, 17, 
39
Cannabis sativa L. Case report Reduction of tics, premonitory 
urges and self-injurious behavior; 
general relaxation; improvement 
of attention and hypersexuality
Hemming et al. 
1993
1 (male) 36 Cannabis sativa L. Case report Symptom free
Müller-Vahl et al. 
1998
64 (55 male, 
9 female)
15-64 Medical cannabis Case series Tic reduction or remission; 
premonitory urges; improvement 
of OCB and ADHD
Müller-Vahl et al. 
1999
1 (male) 25 THC Case report Tic reduction, premonitory 
urges; improvement of attention, 
impulse control, and OCB
Müller-Vahl et al. 
2002a
1 (female) 24 THC (in 
combination with 
amisulpride)
Case report Tic reduction, premonitory urges
Müller-Vahl et al. 
2002b
24 (19 male, 
5 female)
18-68 THC Randomized 
double-blind 
parallel group 
placebo-controlled 
trial
Tic reduction; global 
improvement
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4. Future directions
Larger well-designed controlled studies are urgently needed to confirm available prelimi-
nary results. Further studies should investigate not only the efficacy of CBM in the treatment 
of tics, but also their potency to improve typical psychiatric comorbidities in TS including 
ADHD, OCB, depression, anxiety, sleeping disorders, and rage attacks. Finally, the AE profile 
should be investigated in detail, since from available data, it is suggested that neuropsycho-
logical performance may improve—and not deteriorate—after treatment with CBM in this 
group of patients. So far, it is unknown, which CBM is the most effective and best tolerated in 
patients with TS. However, based on available reports, patients with TS seem to prefer CBM 
with median to high THC content.
Reference Number 
of patients 
(sex)
Age Substance Study design Outcome
Müller-Vahl et al. 
2003b
12 (11 male, 
1 female)
18-66 THC Randomized 
double-blind 
placebo-controlled 
crossover trial
Tic reduction; improvement of 
OCB
Hasan et al. 2010 1 (male) 15 THC (in 
combination with 
aripiprazole and 
risperidone)
Case report Tic reduction, improvement of 
quality of life; treatment with 
methylphenidate was tolerated 
without tic increase
Brunnauer et al. 
2011
1 (male) 42 THC Case report Reduction of tics, improvement 
of concentration and visual 
perception
Trainor et al. 2016 1 (male) 26 Nabiximols Case report Reduction of motor and vocal tics
Abi-Jaoude et al. 
2017
19 (16 
males, 3 
females)
18-51 Medical cannabis Case series, 
structured 
interview
Reduction of tics
Jakubovski and 
Müller-Vahl. 2017
2 (male) 16, 19 THC, medical 
cannabis
Case report Improvement of tics including 
complex vocal tics resulting 
in improved speech fluency, 
co-existing psychiatric conditions 
improved
Kanaan et al. 2017 1 (male) 22 Nabiximols Case report Reduction of tics, improvement 
of quality of life
Szejko et al. 2018 1 (male) 8 THC Case report Reduction of tics, improvement 
of comorbid psychiatric 
conditions (ADHD, depression), 
improvement of quality of life
Szejko et al. 
(submitted to 
Frontiers in 
Psychiatry)
1 (male) 12 THC, medical 
cannabis
Case report Reduction of tics, improvement 
of sleeping problems
Table 1. Case studies employing CBM in TS.
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Currently, a large randomized controlled trial in Germany is recruiting to further investi-
gate efficacy and safety of nabiximols in patients with TS (ClinicalTrials.gov Identifier: 
NCT03087201). In this study, in addition, patients’ fitness to drive will be investigated after 
treatment with nabiximols.
While all published studies investigated the effects of different synthetic or plant-derived can-
nabinoids in the treatment of TS, unpublished data from a single dose pilot study in 20 adult 
patients suggests that also modulators of the endocannabinoid system—such as inhibitors of 
the monoacylglycerol lipase (MGLL)— might be effective in the treatment of TS (ClinicalTrials.
gov Identifier: NCT03058562).
5. Conclusions
There is increasing evidence that CBM might be a promising new treatment strategy for 
patients with TS. However, larger well-designed controlled studies are urgently needed 
to confirm preliminary results. However, already today, a substantial number of patients 
use CBM, either prescribed off-label or no-label under the guidance of the treating phy-
sician or as a self-medication without supervision of a medical doctor. Physicians, who 
treat patients with tic disorders and TS, should actively ask their patients about possible 
use of cannabis, since it is well known that many patients with TS use complementary or 
alternative treatments without informing their doctor [57]. If patients with TS report about 
(illegal) self-medication with cannabis, treating physicians should inform their patients 
about legal treatment options and available routes of intake without the risks associated 
with smoking.
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